FDA Purple Book · Reference family
risankizumab-rzaa (Skyrizi)
risankizumab-rzaa is an FDA-licensed reference biologic from AbbVie Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2025
Reference approved
Reference product
351(a)BLA 761105
Skyrizi risankizumab-rzaa
AbbVie Inc.
- Approved
- Sep 03, 2025
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for risankizumab-rzaa, in chronological order.
Reference approval
Approval date of the reference risankizumab-rzaa product.
9 mo ago
Frequently asked questions
Are there biosimilars approved for risankizumab-rzaa (Skyrizi)?
No 351(k) biosimilars or interchangeable biosimilars referencing risankizumab-rzaa are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.